Drugs / CTx-1301
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05286762 Comparator | Aug 2023 → Feb 2024 | attention deficit-hyperactivity disorder | Cingulate Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT05631626 Comparator | Dec 2022 → Jun 2023 | attention deficit-hyperactivity disorder | Cingulate Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-08-06 | BDD Pharma Ltd | NDA Filing for Advanced ADHD Treatment, CTx-1301 underpinned by BDD’s OralogiK™ Platform. bddpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTx-1301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05631626 ↗ |
| Known as | Dexmethylphenidate | “Using CTx-1301 (Dexmethylphenidate)” NCT05631626 ↗1“Using CTx-1301 (Dexmethylphenidate)” NCT05286762 ↗ |